期刊
MULTIPLE SCLEROSIS AND RELATED DISORDERS
卷 53, 期 -, 页码 -出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.msard.2021.103072
关键词
Multiple sclerosis; Fingolimod; Cryptococcal meningoencephalitis; Immune reconstitution inflammatory syndrome
Fingolimod is an oral medication commonly used to treat multiple sclerosis by sequestering certain subsets of lymphocytes. However, post-discontinuation may lead to opportunistic infections like cryptococcal meningitis and IRIS. Surveillance and risk mitigation strategies are recommended.
Fingolimod is an oral medication for multiple sclerosis that sequesters certain subsets of lymphocytes in lymph nodes, reducing egress into blood and their subsequent CNS migration. The initial multi-site randomized Phase III controlled trials found rates of infection similar to those in control groups. However, post-marketing surveillance has revealed an association with several opportunistic infections, including cryptococcosis. We report a case of fingolimod-related cryptococcal meningoencephalitis and IRIS after drug discontinuation and suggest a surveillance and risk mitigation strategy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据